canertinib dihydrochloride has been researched along with chir 258 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (chir 258) | Trials (chir 258) | Recent Studies (post-2010) (chir 258) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 29 | 0 | 24 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | chir 258 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.339 | |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.0808 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.002 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0162 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0011 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.003 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.0134 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0088 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.0065 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0075 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.0045 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0303 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.002 | |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and chir 258
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |